{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-005108","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.938633+00:00","generated_at":"2026-05-27T01:38:16.754065+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA requires Phase 3 efficacy/safety study for Lipocine's LPCN 1154 in PPD","bullets":["FDA advised that an efficacy and safety study in target population is needed for 505(b)(2) NDA submission, beyond prior PK bridge data.","Lipocine is now planning a Phase 3 safety and efficacy study for oral LPCN 1154 (brexanolone) for postpartum depression.","CEO stated study could support product labeling, exclusivity for 48-hour oral treatment, and also investigate anxiety disorders.","Previous expectations were to discuss NDA package in Q1 2025; new guidance adds clinical trial requirement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-005108","json":"https://secwatch.observer/filing/0001493152-25-005108.json","markdown":"https://secwatch.observer/filing/0001493152-25-005108.md","text":"https://secwatch.observer/filing/0001493152-25-005108.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225005108/0001493152-25-005108-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225005108/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:38:16.754065+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}